Another COVID-19 vaccine shows promise

Embargoed until: Publicly released: 2021-01-14 09:00

International

CC-0

Interim results of a phase 1-2a trial of a COVID-19 candidate vaccine, Ad26.COV2.S, suggest it can provoke a neutralising antibody response in 90 per cent of recipients 29 days after administration, reaching 100 per cent after 57 days. And white blood cell responses were boosted in 76 - 83 per cent of recipients 14 days after administration. These trials were focused on the vaccine candidate's safety and ability to produce immune responses, and the results suggest it should be developed further, the authors say.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: NEJM

Research:Paper

Organisation/s: Janssen Vaccines and Prevention, the Netherlands

Funder: Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.

Media Contact/s

Contact details are only visible to registered journalists.